An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations

References

• Shier AC, Reichenbacher T, Ghuman HS, et al. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2013;5:JCNSD–S6691.
   Google Scholar
• Schweri MM, Skolnick P, Rafferty MF, et al. [3H] Threo‐(±)‐methylphenidate binding to 3, 4‐dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem. 1985;45(4):1062–1070.
   PubMed Web of Science ®Google Scholar
• Izenwasser S, Werling LL, Cox BM. Comparison of the effects of cocaine and other inhibitors of dopamine uptake in rat striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal cortex. Brain Res. 1990;520(1–2):303–309.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52(6):456–463.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. 2017 national survey on drug use and health: detailed tables. Substance abuse and mental health services administration. Rockville, MD. 2018.
   Google Scholar
• Arria AM, Wish ED. Nonmedical use of prescription stimulants among students. Pediatr Ann. 2006;35(8):565–571.
   PubMed Web of Science ®Google Scholar
• Acosta DL, Fair CN, Gonzalez CM, et al. Nonmedical use of d-amphetamines and methylphenidate in medical students. P R Health Sci J. 2019;38(3):185–188.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. The food and drug administration solicits input on potential role for abuse-deterrent formulations of central nervous system stimulants; establishment of a public docket, request for comments. Fed Regist. 2019.
   Google Scholar
• Goodman DW. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T. 2010;35(5):273–287.
   PubMedGoogle Scholar
• Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011;15(4):286–294.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–418.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427.
   PubMed Web of Science ®Google Scholar
• Ermer JC, Dennis K, Haffey MB, et al. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig. 2011;31(6):357–370.
   PubMed Web of Science ®Google Scholar
• Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3(5):386.
   PubMed Web of Science ®Google Scholar
• Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36(1):41–50.
   PubMed Web of Science ®Google Scholar
• Meririnne E, Kankaanpää A, Seppälä T. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1-and D2-receptor antagonists. J Pharmacol Exp Ther. 2001;298(2):539–550.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1(1):2.
   PubMed Web of Science ®Google Scholar
• Zhu J, Spencer TJ, Liu-Chen LY, et al. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology. 2011;61(1–2):283–292.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVane CL, Ramamoorthy S, et al. The psychostimulant d-threo-(R, R)-methylphenidate binds as an agonist to the 5HT1A receptor. Die Pharmazie- Int J Pharm Sci. 2009;64(2):123–125.
   Google Scholar
• Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. Eur J Pharmacol. 2007;571(1):25–28.
   PubMed Web of Science ®Google Scholar
• Sandoval V, Riddle EL, Hanson GR, et al. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci. 2002;22(19):8705–8710.
   PubMed Web of Science ®Google Scholar
• Faraj BA, Israili ZH, Perel JM, et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther. 1974;191(3):535–547.
   PubMed Web of Science ®Google Scholar
• Redalieu E, Bartlett MF, Waldes LM, et al. A study of methylphenidate in man with respect to its major metabolite. Drug Metab Dispos. 1982;10(6):708–709.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceutical Company. Ritalin (methylphenidate hydrochloride). East Hanover, NJ: Novartis Pharmaceuticals Company; 1955.
   Google Scholar
• Census Bureau. The national survey of children’s health. 2018 [cited 2019 Dec 13]. Available from: https://www.census.gov/data/datasets/2018/demo/nsch/nsch2018.html
   Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Attention deficit/hyperactivity disorder. In: Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2019 Dec 13. DOI:https://doi.org/10.1176/appi.books.9780890425596.dsm05.
   Google Scholar
• Maia CRM, Cortese S, Caye A, et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. J Atten Disord. 2017;21(1):3–13.
   PubMed Web of Science ®Google Scholar
• Coghill DR, Seth S, Pedroso S, et al. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry. 2014;76(8):603–615.
   PubMed Web of Science ®Google Scholar
• Pievsky MA, McGrath RE. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis. Neurosci Biobehav Rev. 2018;90:447–455.
   PubMed Web of Science ®Google Scholar
• Fredriksen M, Peleikis DE. Long‐term pharmacotherapy of adults with attention deficit hyperactivity disorder: a literature review and clinical study. Basic Clin Pharmacol Toxicol. 2016;118(1):23–31.
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883–892.
   PubMed Web of Science ®Google Scholar
• Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981–989.
   PubMed Web of Science ®Google Scholar
• Punja S, Zorzela L, Hartling L, et al. Long-acting versus short-acting methylphenidate for pediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open. 2013;3(3):e002312.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health. HHS Publication No. PEP19-5068, NSDUH Series H-54. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019 Dec 16. Available from: https://www.samhsa.gov/data
   Google Scholar
• Teter CJ, McCabe SE, Boyd CJ, et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacother J Human Pharmacol Drug Ther. 2003;23(5):609–617.
   Google Scholar
• FDA. Assessment of abuse potential of drugs: guidance for industry. Clin Med. 2017:5–10.
   Google Scholar
• Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non–drug-abusing humans. J Clin Psychopharmacol. 2001;21(3):273–286.
   PubMed Web of Science ®Google Scholar
• Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol. 1998;6(1):32.
   PubMed Web of Science ®Google Scholar
• Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol. 2001;9(1):59.
   PubMed Web of Science ®Google Scholar
• Rush CR, Kelly TH, Hays LR, et al. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend. 2002;67(3):311–322.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Fillmore MT, Glaser PEA, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol. 2004;18:534–543.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Glaser PEA, et al. Discriminative-stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol. 2005;13:56–64.
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Durell TM, et al. Discriminative-stimulus, self- reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol. 2006;14:136–147.
   PubMed Web of Science ®Google Scholar
• Sevak RJ, Stoops WW, Hays LR, et al. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther. 2009;328(3):1007–1018.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PEA, Rush CR. Reinforcing, subject-rated and physiological effects of intranasal methylphenidate: A dose response analysis. Drug Alcohol Depend. 2003;71:179–186.
   PubMed Web of Science ®Google Scholar
• Lile JA, Babalonis S, Emurian C, et al. Comparison of the behavioral and cardiovascular effects of intranasal and oral d‐amphetamine in healthy human subjects. J Clin Pharmacol. 2011;51(6):888–898.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Hitzemann RJ, et al. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res. 1997;3(1):49–54.
   Web of Science ®Google Scholar
• Vogel M, Bucher P, Strasser J, et al. Similar and different? Subjective effects of methylphenidate and cocaine in opioid-maintained patients. J Psychoactive Drugs. 2016;48(2):93–100.
   PubMed Web of Science ®Google Scholar
• Hill HE, Haertzen CA, Wolbach AB, et al. The addiction research center inventory. Psychopharmacologia. 1963;4(3):184–205.
   PubMedGoogle Scholar
• McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states (POMS). San Diego: Educational and Industrial Testing Service; 1971.
   Google Scholar
• Foltin RW, Fishcman MW. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 1991;28:3–48.
   PubMed Web of Science ®Google Scholar
• Stoops WW. Reinforcing effects of stimulants in humans: sensitivity of progressive-ratio schedules. Exp Clin Psychopharmacol. 2008;16(6):503.
   PubMed Web of Science ®Google Scholar
• Kollins SH, English J, Robinson R, et al. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl). 2009;204(1):73.
   PubMed Web of Science ®Google Scholar
• Bolin BL, Alcorn JL III, Reynolds AR, et al. Human drug discrimination: A primer and methodological review. Exp Clin Psychopharmacol. 2016;24(4):214.
   PubMed Web of Science ®Google Scholar
• Stiefel G, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821–842.
   PubMed Web of Science ®Google Scholar
• Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002;14(2):219–223.
   PubMed Web of Science ®Google Scholar
• Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4):662–666.
   PubMed Web of Science ®Google Scholar
• Krinzinger H, Hall CL, Groom MJ, et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev. 2019;107:945–968.
   PubMed Web of Science ®Google Scholar
• Benson K, Flory K, Humphreys KL, et al. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev. 2015;18(1):50–76.
   PubMed Web of Science ®Google Scholar
• Linssen AMW, Vuurman EFPM, Sambeth A, et al. Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology (Berl). 2012;221(4):611–619.
   PubMed Web of Science ®Google Scholar
• Agay N, Yechiam E, Carmel Z, et al. Methylphenidate enhances cognitive performance in adults with poor baseline capacities regardless of attention-deficit/hyperactivity disorder diagnosis. J Clin Psychopharmacol. 2014;34(2):261–265.
   PubMed Web of Science ®Google Scholar
• Arria AM, Caldeira KM, Vincent KB, et al. Do college students improve their grades by using prescription stimulants nonmedically? Addict Behav. 2017;65:245–249.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Abuse-deterrent opioid – evaluation and labeling; guidance for industry. Clin Med. 3–17.
   Google Scholar
• Spencer TJ, Bhide P, Zhu J, et al. Opiate antagonists do not interfere with the clinical benefits of stimulants in ADHD: A double-blind, placebo-controlled trial of the mixed opioid receptor antagonist naltrexone. J Clin Psychiatry. 2018;79(1):16m11012.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol. 1998;6(4):367.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman JE, Ciccone P, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387–395.
   PubMed Web of Science ®Google Scholar